MedWatch

ALK's tablet trial in Ukraine set to continue

Despite the conflict between Russia and Ukraine, the allergy firm has ongoing pediatric trials in both countries. CEO Carsten Hellmann was initially surprised that this was possible in a warzone.

On the face of it, conducting trials in Russia and Ukraine ought to be difficult right now – but somehow, ALK is managing it | Photo: SERGEI SUPINSKY/AFP / AFP

ALK is currently testing its tablet against house dust mite allergies in children in a large phase III study taking place across the US and Europe. The company finished enrollment earlier this year – and among the patient population are people from Ukraine and Russia.

In connection with ALK’s recently publicized financial report, it was stated that the number of people who had had to leave the trial due to the ongoing war in Ukraine was minimal.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs